Turkish Journal of Nephrology
Case Report

Everolimus Toxicity in a Kidney Transplant Recipient Treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Chronic Hepatitis C

1.

Division of Gastroenterology, Akdeniz University School of Medicine, Antalya, Turkey

2.

Division of Nephrology, Akdeniz University School of Medicine, Antalya, Turkey

Turkish J Nephrol 2020; 29: 82-83
DOI: 10.5152/turkjnephrol.2020.3567
Read: 1549 Downloads: 704 Published: 11 February 2020

The incidence of chronic hepatitis C virus (HCV) infection in kidney transplant recipients is 5%-15%, and HCV is an important risk factor for posttransplant kidney issues. Novel interferon-free regimens with direct-acting oral antiviral agents have extremely high response rates in solid organ transplant patients with HCV; however, drug–drug interactions, particularly with immunosuppressive agents, should be considered when deciding the treatment. Here we report a case of severe everolimus toxicity in a kidney transplant recipient receiving ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment.

Cite this article as: Akın M, Buldukoğlu OÇ, Adanır H, Yalçınkaya T, Yılmaz VT, Yıldırım B, et al. Everolimus Toxicity in a Kidney Transplant Recipient Treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Chronic Hepatitis C. Turk J Nephrol 2020; 29(1): 82-3.

Files
EISSN 2667-4440